Michael F. Drummond
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Michael F. Drummond has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Marco Barbieri
2 shared publicationsMark Sculpher
2 shared publicationsA. Mark Fendrick
1 shared publicationAndrea Manca
University of York
1 shared publicationBengt Jonsson
Stockholm School of Economics, Stockholm, Sweden
1 shared publicationBengt Jönsson
Stockholm School of Economics, Stockholm, Sweden
1 shared publication
Latest Publications
- 1 September 2005
- Published by SAGE Publications in Medical Decision Making
- Vol. 25 (5) , 520-533
Analytic Choices in Economic Models of Treatments for Rheumatoid Arthritis: What Makes a Difference?
Objectives. To compare the analytic judgments, data, and assumptions of different models used in the economic evaluation of infliximab, one of a new class of drugs for rheumatoid arthritis (RA). Methods. A detailed assessment was made of 4 models, 1 submitted (in a reimbursement dossier) by the manufacturer, 1 produced by an independent academic group, and 2 recently published in the literature. Factors considered included the key data inputs, assumptions about the sequencing of treatments for RA, the methods used to calculate health utilities, and the estimation of cost offsets. Results. Two of the 4 models, although embodying different methodological approaches, gave fairly similar results (approximately £25,000–£35,000 cost per additional quality-adjusted life year [QALY] gained). The other 2 models, both by an independent academic group, gave much higher estimates, ranging from £50,000 to £60,000 to more than £100,000 per additional QALY. The differences appeared to depend mainly on differences in model structure, the assumptions about the positioning of infliximab in the treatment sequence, and the relationship between Health Assessment Questionnaire (HAQ) states and QALYs. Conclusions. Economic models of treatments for RA incorporate different key data inputs and analytic judgments. However, convergence was observed in some of the estimates produced by the models, particularly when adjustments were made for some of the differences in input parameters. Nevertheless, differences in the choice of model structure and in key assumptions also had a major impact on results. Therefore, more discussion is needed to reach a consensus on some of these methodological issues.
- 1 September 2005
- Published by SAGE Publications in Medical Decision Making
- Vol. 25 (5) , 520-533
Analytic Choices in Economic Models of Treatments for Rheumatoid Arthritis: What Makes a Difference?
Objectives. To compare the analytic judgments, data, and assumptions of different models used in the economic evaluation of infliximab, one of a new class of drugs for rheumatoid arthritis (RA). Methods. A detailed assessment was made of 4 models, 1 submitted (in a reimbursement dossier) by the manufacturer, 1 produced by an independent academic group, and 2 recently published in the literature. Factors considered included the key data inputs, assumptions about the sequencing of treatments for RA, the methods used to calculate health utilities, and the estimation of cost offsets. Results. Two of the 4 models, although embodying different methodological approaches, gave fairly similar results (approximately £25,000–£35,000 cost per additional quality-adjusted life year [QALY] gained). The other 2 models, both by an independent academic group, gave much higher estimates, ranging from £50,000 to £60,000 to more than £100,000 per additional QALY. The differences appeared to depend mainly on differences in model structure, the assumptions about the positioning of infliximab in the treatment sequence, and the relationship between Health Assessment Questionnaire (HAQ) states and QALYs. Conclusions. Economic models of treatments for RA incorporate different key data inputs and analytic judgments. However, convergence was observed in some of the estimates produced by the models, particularly when adjustments were made for some of the differences in input parameters. Nevertheless, differences in the choice of model structure and in key assumptions also had a major impact on results. Therefore, more discussion is needed to reach a consensus on some of these methodological issues.
- 1 July 2005
- Published by Wolters Kluwer Health in Medical Care
- Vol. 43 (7) , 5
Common Methodological Flaws in Economic Evaluations
Economic evaluations are increasingly being used by those bodies such as government agencies and managed care groups that make decisions about the reimbursement of health technologies. However, several reviews of economic evaluations point to numerous deficiencies in the methodology of studies or the failure to follow published methodological guidelines. This article, written for healthcare decision-makers and other users of economic evaluations, outlines the common methodological flaws in studies, focussing on those issues that are likely to be most important when deciding on the reimbursement, or guidance for use, of health technologies. The main flaws discussed are: (i) omission of important costs or benefits; (ii) inappropriate selection of alternatives for comparison; (iii) problems in making indirect comparisons; (iv) inadequate representation of the effectiveness data; (v) inappropriate extrapolation beyond the period observed in clinical studies; (vi) excessive use of assumptions rather than data; (vii) inadequate characterization of uncertainty; (viii) problems in aggregation of results; (ix) reporting of average cost-effectiveness ratios; (x) lack of consideration of generalizability issues; and (xi) selective reporting of findings. In each case examples are given from the literature and guidance is offered on how to detect flaws in economic evaluations.
- 1 July 2005
- Published by Wolters Kluwer Health in Medical Care
- Vol. 43 (7) , 5
Common Methodological Flaws in Economic Evaluations
Economic evaluations are increasingly being used by those bodies such as government agencies and managed care groups that make decisions about the reimbursement of health technologies. However, several reviews of economic evaluations point to numerous deficiencies in the methodology of studies or the failure to follow published methodological guidelines. This article, written for healthcare decision-makers and other users of economic evaluations, outlines the common methodological flaws in studies, focussing on those issues that are likely to be most important when deciding on the reimbursement, or guidance for use, of health technologies. The main flaws discussed are: (i) omission of important costs or benefits; (ii) inappropriate selection of alternatives for comparison; (iii) problems in making indirect comparisons; (iv) inadequate representation of the effectiveness data; (v) inappropriate extrapolation beyond the period observed in clinical studies; (vi) excessive use of assumptions rather than data; (vii) inadequate characterization of uncertainty; (viii) problems in aggregation of results; (ix) reporting of average cost-effectiveness ratios; (x) lack of consideration of generalizability issues; and (xi) selective reporting of findings. In each case examples are given from the literature and guidance is offered on how to detect flaws in economic evaluations.
- 26 April 2005
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 21 (2) , 165-171
Increasing the generalizability of economic evaluations: Recommendations for the design, analysis, and reporting of studies
Objectives:Health technology assessment (HTA) is increasingly an international activity, and HTA agencies collaborate to avoid unnecessary duplication of effort. However, the sharing of the results from HTAs raises questions about their generalizability; namely, are the results of an HTA undertaken in one country relevant to another?Methods:This study presents recommendations for increasing the generalizability of economic evaluations. They represent an important component of HTAs and are commonly thought to have limited generalizability.Results:Recommendations are given for studies using patient-level data (i.e., evaluations conducted alongside clinical trials) and for studies using decision analytic modeling.Conclusions:If implemented, the recommendations would increase the value for investments in HTA.
- 26 April 2005
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 21 (2) , 165-171
Increasing the generalizability of economic evaluations: Recommendations for the design, analysis, and reporting of studies
Objectives:Health technology assessment (HTA) is increasingly an international activity, and HTA agencies collaborate to avoid unnecessary duplication of effort. However, the sharing of the results from HTAs raises questions about their generalizability; namely, are the results of an HTA undertaken in one country relevant to another?Methods:This study presents recommendations for increasing the generalizability of economic evaluations. They represent an important component of HTAs and are commonly thought to have limited generalizability.Results:Recommendations are given for studies using patient-level data (i.e., evaluations conducted alongside clinical trials) and for studies using decision analytic modeling.Conclusions:If implemented, the recommendations would increase the value for investments in HTA.
- Open Access
- 1 November 2003
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 42 (90003) , 60iii-63
The use of health economic information by reimbursement authorities
The increasing costs of health-care and the need for cost containment have resulted in a ‘fourth hurdle’ in the establishment of drug approval and reimbursement policies. This hurdle is the demonstration of a drug’s cost-effectiveness through the process of economic evaluation. The role of models in the economic evaluation of pharmaceuticals is becoming increasingly accepted with the recent trend towards developing models with greater transparency and clinical relevance. However, health-care decisions do not, and should not, rely solely on the cost-effectiveness of a drug or intervention. Factors such as disease severity, availability of alternative treatment strategies, cost of drugs to patients, compliance with therapy and patients’ satisfaction with overall treatment effectiveness should also be considered, and in some cases can be incorporated into economic evaluation. The Arthritis Cost Consequences Evaluation System (ACCES) is provided as an example of the attributes and limitations that should be considered in determining the usefulness of a model for economic evaluations with the purpose of determining reimbursement policy decisions.
- 1 November 2003
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 42 (90003) , 60iii-63
Open AccessThe use of health economic information by reimbursement authorities
The increasing costs of health-care and the need for cost containment have resulted in a ‘fourth hurdle’ in the establishment of drug approval and reimbursement policies. This hurdle is the demonstration of a drug’s cost-effectiveness through the process of economic evaluation. The role of models in the economic evaluation of pharmaceuticals is becoming increasingly accepted with the recent trend towards developing models with greater transparency and clinical relevance. However, health-care decisions do not, and should not, rely solely on the cost-effectiveness of a drug or intervention. Factors such as disease severity, availability of alternative treatment strategies, cost of drugs to patients, compliance with therapy and patients’ satisfaction with overall treatment effectiveness should also be considered, and in some cases can be incorporated into economic evaluation. The Arthritis Cost Consequences Evaluation System (ACCES) is provided as an example of the attributes and limitations that should be considered in determining the usefulness of a model for economic evaluations with the purpose of determining reimbursement policy decisions.
- Open Access
- 1 July 2003
- Published by Elsevier in Value in Health
- Vol. 6 (s1) , S74-S77
Moving Beyond the Drug Budget Silo Mentality in Europe
- 1 July 2003
- Published by Elsevier in Value in Health
- Vol. 6 (s1) , S74-S77
Open AccessMoving Beyond the Drug Budget Silo Mentality in Europe
- 1 July 2003
- Published by Elsevier in Value in Health
- Vol. 6 (4) , 407-416
Use of Pharmacoeconomics Information—Report of the ISPOR Task Force on Use of Pharmacoeconomic/Health Economic Information in Health-Care Decision Making
- 1 July 2003
- Published by Elsevier in Value in Health
- Vol. 6 (4) , 407-416
Use of Pharmacoeconomics Information—Report of the ISPOR Task Force on Use of Pharmacoeconomic/Health Economic Information in Health-Care Decision Making
- 1 June 2003
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 4 (2) , 67-69
Will there ever be a European drug pricing and reimbursement agency?
- 1 June 2003
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 4 (2) , 67-69
Will there ever be a European drug pricing and reimbursement agency?
- 1 June 2002
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 3 (2) , 137-138
Time for a change in drug licensing requirements?
- 1 June 2002
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 3 (2) , 137-138
Time for a change in drug licensing requirements?
- 1 June 2002
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 3 (2) , 142
A final comment
- 1 June 2002
- Published by Springer Nature in The European Journal of Health Economics
- Vol. 3 (2) , 142
A final comment
- 1 October 2001
- Published by Springer Nature in Current Oncology Reports
- Vol. 3 (5) , 410-413
Conflict of interest in industrysponsored economic evaluations: Real or imagined?
As industry sponsorship of pharmacoeconomic studies has increased, concerns have been raised about potential biases, owing to the conflicts of interest that this sponsorship creates. A review of the literature indicates that there are some causes for concern, given the fact that most pharmacoeconomic studies report positive findings for the sponsor’s drug. However, a more detailed analysis suggests that, although the methodologic quality of some published studies may be poor, the main reason for positive results is that companies only sponsor economic studies where a positive outcome is likely. Therefore, it is concluded that the best way of dealing with perceptions of sponsorship bias is not increased rhetoric, but rather increased public funding for economic evaluation of medicines, thereby creating a true mixed economy for research funding in this field.
- 1 October 2001
- Published by Springer Nature in Current Oncology Reports
- Vol. 3 (5) , 410-413
Conflict of interest in industrysponsored economic evaluations: Real or imagined?
As industry sponsorship of pharmacoeconomic studies has increased, concerns have been raised about potential biases, owing to the conflicts of interest that this sponsorship creates. A review of the literature indicates that there are some causes for concern, given the fact that most pharmacoeconomic studies report positive findings for the sponsor’s drug. However, a more detailed analysis suggests that, although the methodologic quality of some published studies may be poor, the main reason for positive results is that companies only sponsor economic studies where a positive outcome is likely. Therefore, it is concluded that the best way of dealing with perceptions of sponsorship bias is not increased rhetoric, but rather increased public funding for economic evaluation of medicines, thereby creating a true mixed economy for research funding in this field.